Navigation Links
Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
Date:11/19/2010

the age of 60 who were able to maintain normal daily activities (KPS>80 percent) at the time of enrollment achieved a significant increase in median overall survival time (8.8 vs. 6.6 months, n=110, p< 0.01) and in the 1-year survival rate (35 percent vs. 20 percent, n=110, p< 0.01) when treated with TTF Therapy versus effective chemotherapies. TTF therapy also produced a significant increase in survival time for patients who had failed treatment with bevacizumab (Avastin; Roche) prior to enrollment (4.4 vs. 3.1 months, n=44, p< 0.02). Patients enrolled in the study also reported superior quality of life scores (EORTC QLQ-C30) across a range of lifestyle and symptom categories for TTF therapy compared to the chemotherapy-treated control group.

"The data presented at SNO further validate TTF therapy as a potential treatment option for patients with recurrent glioblastoma tumors," said Asaf Danziger, chief executive officer of Novocure, the trial sponsor. "The suggested improvement in quality of life scores reported by patients receiving TTF therapy is particularly important given the nature of this disease and the strong desire among patients and their caregivers to avoid the side-effects of chemotherapy and radiation."

TTF therapy has been shown in vitro to slow and reverse tumor cell proliferation by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low-intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.

Novocure is now sponsoring a second phase III study of TTF therapy at 26 centers in the US, Europe, and Israel. This study will enroll 283 patients with newly diagnosed glioblastoma tumors. Patients will be randomized (2 to 1) to receive TTF therapy and temozolomide (Temo
'/>"/>

Contact: Frank Leonard
frank@novo-cure.com
917-656-3518
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Professor John Shine wins 2010 Prime Ministers Prize for Science
2. CancerCare names Jefferson professor Physician of the Year
3. Professor Cesare Montecucco to receive the 2011 Paul Ehrlich and Ludwig Darmstaedter Prize
4. UT professor defines play, discovers even turtles need recess
5. Virginia Tech professor discovers new TB pathogen
6. Drug to treat alcoholism goal of UH professors research
7. K-State professors book is first to explore Two-Spirit literature in Northwest native groups
8. Louisiana Tech kinesiology professor receives national editorial excellence award
9. WPI computer science professor receives HP Labs Innovation Research Award
10. Linguistics professor examines manufacturers prescription drug websites
11. NJIT professor heads panel studying sudden car acceleration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader ... designers are thrilled to have it lead the wedding dress ... collection of prom dresses for the global market. , “The ... vision and he focuses on continuing the goal of operational ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... With major surgery,now occurring at a rate of ... people - and studies indicating that a significant percentage ... (WHO),launched a new safety checklist for surgical teams to ... to make surgery safer around the world., To ...
... Cuts and Caps Moves Forward, ALEXANDRIA, Va., ... today hailed passage of the Medicare,Improvements for Patients ... House of,Representatives as a significant step forward for ... Senate to quickly follow suit., HR 6331 ...
... SkinMedica(R), Inc., launches,a new informational web site, ... Complex(R). The site is designed to,communicate with ... of the,science and efficacy of NouriCel-MD(R), the ... growing TNS(R) Collection., TNSRecoveryComplex.com features eight ...
... June 24 Alan J. Zuccari,President & CEO of ... (PAC) member for the American Health Care Association this,June ... an honor to be recognized by the AHCA," said ... such an outstanding organization whose,ultimate focus is providing quality ...
... with Patient Outcome in Neuroblastoma , Expression of ... patients whose tumors lacked CHD5 expression were more likely ... patients whose tumors expressed CHD5. , Neuroblastoma tumors often ... arm of chromosome 1, called 1p36.31. Garrett Brodeur, M.D., ...
... shot targets the gut,s immune system , , TUESDAY, June 24 ... metastatic colon cancer appears to work in mice, researchers ... acts on the immune system in the intestines, a separate ... , "There are two independent immune systems in our bodies, ...
Cached Medicine News:Health News:WHO Creates New Surgical Tool to Make Operations Safer Everywhere 2Health News:WHO Creates New Surgical Tool to Make Operations Safer Everywhere 3Health News:Physical Therapists Applaud House Passage of Medicare Package 2Health News:SkinMedica(R) Launches New Informational Web Site 2Health News:SkinMedica(R) Launches New Informational Web Site 3Health News:Alan J. Zuccari Featured by the American Health Care Association as a June PAC Member 2Health News:Also in the June 24 JNCI 2Health News:Also in the June 24 JNCI 3Health News:Also in the June 24 JNCI 4Health News:Also in the June 24 JNCI 5Health News:Vaccine Stops Colon Cancer's Spread in Mice 2
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
(Date:1/22/2015)... Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... on Omega-3 therapies for cardiovascular disease and overall health is ... accomplishments in 2014 and its outlook for 2015 from the ... Shareholders, We would like to take this opportunity ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has ... Market by Product, Application, Technology, End User - Global ... The infectious disease diagnostics market is expected ... million by 2019 from $12,422.8 million in 2014. Increase ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... YORK, Dec. 21 Intra-Cellular Therapies, Inc. (ITI) announced ... from a recently completed Phase I clinical study demonstrating ... targets in the living human brain. These key ... and related disorders. Using positron emission tomography (PET) ...
... , , , BEIJING, Dec. 21 ... biopharmaceutical products in China, announced today,that Sinovac was selected by ... companies listed overseas for 2009. The honor was given to,Sinovac ... The "Competitiveness Measure" is the measuring ...
Cached Medicine Technology:Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders 2Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders 3Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders 4Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders 5Sinovac Named One of China's Top 10 Most Competitive Companies Listed Overseas in 2009 2Sinovac Named One of China's Top 10 Most Competitive Companies Listed Overseas in 2009 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: